BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16789734)

  • 1. Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors.
    Gu YG; Weitzberg M; Clark RF; Xu X; Li Q; Zhang T; Hansen TM; Liu G; Xin Z; Wang X; Wang R; McNally T; Zinker BA; Frevert EU; Camp HS; Beutel BA; Sham HL
    J Med Chem; 2006 Jun; 49(13):3770-3. PubMed ID: 16789734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression, purification, and characterization of human acetyl-CoA carboxylase 2.
    Kim KW; Yamane H; Zondlo J; Busby J; Wang M
    Protein Expr Purif; 2007 May; 53(1):16-23. PubMed ID: 17223360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as acetyl-coA carboxylase inhibitors--improvement of cardiovascular and neurological liabilities via structural modifications.
    Gu YG; Weitzberg M; Clark RF; Xu X; Li Q; Lubbers NL; Yang Y; Beno DW; Widomski DL; Zhang T; Hansen TM; Keyes RF; Waring JF; Carroll SL; Wang X; Wang R; Healan-Greenberg CH; Blomme EA; Beutel BA; Sham HL; Camp HS
    J Med Chem; 2007 Mar; 50(5):1078-82. PubMed ID: 17298049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression analysis in rats treated with experimental acetyl-coenzyme A carboxylase inhibitors suggests interactions with the peroxisome proliferator-activated receptor alpha pathway.
    Waring JF; Yang Y; Healan-Greenberg CH; Adler AL; Dickinson R; McNally T; Wang X; Weitzberg M; Xu X; Lisowski A; Warder SE; Gu YG; Zinker BA; Blomme EA; Camp HS
    J Pharmacol Exp Ther; 2008 Feb; 324(2):507-16. PubMed ID: 18025247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synthesis and structure-activity relationship studies of selective acetyl-CoA carboxylase inhibitors containing 4-(thiazol-5-yl)but-3-yn-2-amino motif: polar region modifications.
    Xu X; Weitzberg M; Keyes RF; Li Q; Wang R; Wang X; Zhang X; Frevert EU; Camp HS; Beutel BA; Sham HL; Gu YG
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1803-7. PubMed ID: 17234407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of genes regulating malonyl-CoA in human skeletal muscle.
    Pender C; Trentadue AR; Pories WJ; Dohm GL; Houmard JA; Youngren JF
    J Cell Biochem; 2006 Oct; 99(3):860-7. PubMed ID: 16721829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase.
    Freeman-Cook KD; Amor P; Bader S; Buzon LM; Coffey SB; Corbett JW; Dirico KJ; Doran SD; Elliott RL; Esler W; Guzman-Perez A; Henegar KE; Houser JA; Jones CS; Limberakis C; Loomis K; McPherson K; Murdande S; Nelson KL; Phillion D; Pierce BS; Song W; Sugarman E; Tapley S; Tu M; Zhao Z
    J Med Chem; 2012 Jan; 55(2):935-42. PubMed ID: 22148323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression, purification, and characterization of human and rat acetyl coenzyme A carboxylase (ACC) isozymes.
    Cheng D; Chu CH; Chen L; Feder JN; Mintier GA; Wu Y; Cook JW; Harpel MR; Locke GA; An Y; Tamura JK
    Protein Expr Purif; 2007 Jan; 51(1):11-21. PubMed ID: 16854592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenoxy thiazole derivatives as potent and selective acetyl-CoA carboxylase 2 inhibitors: Modulation of isozyme selectivity by incorporation of phenyl ring substituents.
    Clark RF; Zhang T; Wang X; Wang R; Zhang X; Camp HS; Beutel BA; Sham HL; Gu YG
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1961-5. PubMed ID: 17267221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals.
    Harwood HJ; Petras SF; Shelly LD; Zaccaro LM; Perry DA; Makowski MR; Hargrove DM; Martin KA; Tracey WR; Chapman JG; Magee WP; Dalvie DK; Soliman VF; Martin WH; Mularski CJ; Eisenbeis SA
    J Biol Chem; 2003 Sep; 278(39):37099-111. PubMed ID: 12842871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice.
    Harada N; Oda Z; Hara Y; Fujinami K; Okawa M; Ohbuchi K; Yonemoto M; Ikeda Y; Ohwaki K; Aragane K; Tamai Y; Kusunoki J
    Mol Cell Biol; 2007 Mar; 27(5):1881-8. PubMed ID: 17210641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.
    Bengtsson C; Blaho S; Saitton DB; Brickmann K; Broddefalk J; Davidsson O; Drmota T; Folmer R; Hallberg K; Hallén S; Hovland R; Isin E; Johannesson P; Kull B; Larsson LO; Löfgren L; Nilsson KE; Noeske T; Oakes N; Plowright AT; Schnecke V; Ståhlberg P; Sörme P; Wan H; Wellner E; Oster L
    Bioorg Med Chem; 2011 May; 19(10):3039-53. PubMed ID: 21515056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased muscle acetyl-coenzyme A carboxylase 2 mRNA and insulin resistance in formerly obese subjects.
    Rosa G; Manco M; Vega N; Greco AV; Castagneto M; Vidal H; Mingrone G
    Obes Res; 2003 Nov; 11(11):1306-12. PubMed ID: 14627750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and synthesis of novel inhibitors of acetyl-CoA carboxylase with in vitro and in vivo efficacy on fat oxidation.
    Keil S; Müller M; Zoller G; Haschke G; Schroeter K; Glien M; Ruf S; Focken I; Herling AW; Schmoll D
    J Med Chem; 2010 Dec; 53(24):8679-87. PubMed ID: 21082864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential activation of recombinant human acetyl-CoA carboxylases 1 and 2 by citrate.
    Locke GA; Cheng D; Witmer MR; Tamura JK; Haque T; Carney RF; Rendina AR; Marcinkeviciene J
    Arch Biochem Biophys; 2008 Jul; 475(1):72-9. PubMed ID: 18455495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome.
    Harwood HJ
    Curr Opin Investig Drugs; 2004 Mar; 5(3):283-9. PubMed ID: 15083594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent biphenyl- and 3-phenyl pyridine-based inhibitors of acetyl-CoA carboxylase.
    Haque TS; Liang N; Golla R; Seethala R; Ma Z; Ewing WR; Cooper CB; Pelleymounter MA; Poss MA; Cheng D
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5872-6. PubMed ID: 19740659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships for a novel series of thiazolyl phenyl ether derivatives exhibiting potent and selective acetyl-CoA carboxylase 2 inhibitory activity.
    Clark RF; Zhang T; Xin Z; Liu G; Wang Y; Hansen TM; Wang X; Wang R; Zhang X; Frevert EU; Camp HS; Beutel BA; Sham HL; Gu YG
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6078-81. PubMed ID: 16973360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LKB1 and the regulation of malonyl-CoA and fatty acid oxidation in muscle.
    Thomson DM; Brown JD; Fillmore N; Condon BM; Kim HJ; Barrow JR; Winder WW
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1572-9. PubMed ID: 17925454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Acetyl-CoA Carboxylase 2 Selective Inhibitor Improves Whole-Body Insulin Resistance and Hyperglycemia in Diabetic Mice through Target-Dependent Pathways.
    Takagi H; Tanimoto K; Shimazaki A; Tonomura Y; Momosaki S; Sakamoto S; Abe K; Notoya M; Yukioka H
    J Pharmacol Exp Ther; 2020 Mar; 372(3):256-263. PubMed ID: 31900320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.